<DOC>
	<DOCNO>NCT02983981</DOCNO>
	<brief_summary>A two-phase , single center , study 20 subject assess 4 week add-on therapy Topicort® BID 12 week BID two consecutive day week patient ≤5 % BSA receive biologic therapy least 24 week</brief_summary>
	<brief_title>Topical Psoriasis Study Patients Receiving Biologic Therapy</brief_title>
	<detailed_description>A two-phase , single center , study 20 subject assess 4 week add-on therapy Topicort® BID 12 week BID two consecutive day week patient ≤5 % BSA receive biologic therapy least 24 week . Adult male female subject moderate severe chronic plaque psoriasis All patient receive Topicort® BID 4 week . After week 4 patient receive Topicort® BID two consecutive day week 12 week .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Desoximetasone</mesh_term>
	<criteria>1 . Male female adult ≥ 18 year age . 2 . Diagnosis chronic plaquetype psoriasis . 3 . Able give write informed consent prior performance study related procedure . 4 . Treated biologic agent minimum 24 week baseline . 5 . Plaquetype psoriasis define screen baseline BSA ≤ 5 % . 6 . Females childbearing potential ( FCBP ) must negative pregnancy test Screening Baseline . FCBP engage activity conception possible must use one approve contraceptive option : hormonal contraception ; intrauterine device ( IUD ) ; tubal ligation ; partner 's vasectomy ; Male female condom diaphragm spermicide , cervical cap spermicide , contraceptive sponge spermicide . 7 . Subject must general good health ( except psoriasis ) judge Investigator , base medical history , physical examination . 1 . &gt; 5 % Body Surface Area 2 . Any condition , would place subject unacceptable risk he/she participate study . 3 . Pregnant breast feeding , consider become pregnant study . 4 . Malignancy history malignancy , except : 1. treat [ ie , cure ] basal cell squamous cell situ skin carcinoma ; 2. treat [ ie , cure ] malignancy evidence recurrence within previous 5 year . 5 . Use investigational drug within 4 week prior randomization , within 5 pharmacokinetic/pharmacodynamic half life , know ( whichever longer ) . 6 . Use oral systemic medication treatment psoriasis within 4 week ( include , limited , oral corticosteroid , methotrexate , acitretin , apremilast cyclosporine ) . 7 . Patient use topical therapy treat within 2 week Baseline Visit ( include , limited , topical corticosteroid , vitamin D analog , retinoids ) . 8 . Patient receive UVB phototherapy within 2 week Baseline . 9 . Patient receive PUVA phototherapy within 4 week Baseline . 10 . Patient known hypersensitivity excipients Topicort Spray® state label .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>